FDA PMA submission is a major de-risking catalyst for this pre-commercial medical device company. Key near-term milestones: (1) FDA acceptance/acknowledgment of the PMA filing (typically 30 days), (2) FDA panel meeting schedule and advisory committee vote, (3) target PDUFA/approval date. The stock has limited float and market cap ($19M), so any positive FDA news could drive outsized moves. Monitor for any FDA 'refuse to file' letter, which would be a material negative. If approved, vCLAS would be the first purpose-built endocardial VT ablation system cleared in the U.S., with a massive market opportunity.
Price Chart
Executive Summary
Adagio Medical announced submission of a Premarket Approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System, supported by FULCRUM-VT pivotal trial data (209 patients, 97.4% acute success, 84.3% 6-month freedom from ICD shocks, 2.4% major adverse events). This is the first-ever PMA submission for a purpose-built VT ablation system targeting a $5.8B market, and the stock has previously received Breakthrough Device Designation.
Key Facts
- Adagio submitted a PMA application to the FDA for the vCLAS Ventricular Ablation System to treat ventricular tachycardia.
- The PMA is supported by the FULCRUM-VT pivotal trial: 209 patients at 20 centers; 97.4% acute clinical success; 84.3% freedom from ICD shocks at 6 months; 2.4% major adverse events; 78% reduction/elimination of anti-arrhythmic drug use.
- The vCLAS system previously received FDA Breakthrough Device Designation.
- This is described as the first PMA submission for a purpose-built VT ablation system in a $5.8B market.
- The vCLAS system is already CE Marked and commercially available in Europe; the PMA seeks U.S. approval.
- The filing is an 8-K with Item 8.01 (Other Events) — no financial statements or offering data.
Financial Impact
No financial figures provided in the filing (pre-revenue stage; no revenue, EPS, or cash position disclosed). The filing cites a $5.8B total addressable market for the vCLAS Ventricular Ablation System.
Risk Factors
- FDA may refuse to file the PMA, triggering a significant downside move.
- Clinical data from a single-arm trial may not meet FDA's bar for safety/effectiveness in a PMA review.
- Company is pre-revenue in the U.S.; no disclosure of cash runway or burn rate.
- Investors face binary outcomes: FDA approval vs. denial/additional trials; high volatility expected.
- Breakthrough Device Designation does not guarantee expedited approval or any approval at all.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-065180 |
| Document: tm2614299d2_ex99-1.htm | 0001104659-26-065180 |
| Document: 0001104659-26-065180-index-headers.html | 0001104659-26-065180 |
| Document: 0001104659-26-065180-index.html | 0001104659-26-065180 |
| Document: 0001104659-26-065180.txt | 0001104659-26-065180 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEF 14A | $0.1253 $0.1208 | ▼ −3.59% | ▼ −2.44% | $0.0967 (−22.83%) |
Oct 1, 2026 25d ago | 8-K | $0.1531 $0.1300 | ▲ +15.09% | ▲ +16.25% | $0.0967 (+36.84%) |
Sep 23, 2026 4w ago | 8-K | $0.2280 $0.1530 | ▲ +32.89% | ▲ +32.22% | $0.0967 (+57.59%) |
Aug 11, 2026 10w ago | 8-K | $0.7190 $0.6460 | ▲ +10.15% | ▲ +9.75% | $0.0967 (+86.55%) |
Jul 13, 2026 15w ago | 10-K/A | $0.5710 $0.5300 | ▼ −7.18% | ▼ −6.40% | $0.0967 (−83.06%) |
May 21, 2026 22w ago | 8-K | $0.8410 $0.7699 | ▼ −8.45% | ▼ −10.13% | $0.0967 (−88.50%) |
May 12, 2026 23w ago | 8-K | $0.9230 $0.8830 | ▼ −4.33% | ▼ −4.41% | $0.0967 (−89.52%) |
Apr 27, 2026 26w ago | 8-K | $1.15 $0.9410 | ▼ −18.17% | ▼ −18.57% | $0.0967 (−91.59%) |
Apr 8, 2026 28w ago | 8-K | $1.41 $1.43 | ▲ +1.42% | ▼ −2.10% | $0.0967 (−93.14%) |
Apr 6, 2026 29w ago | EFFECT | $1.25 $1.33 | ▼ −6.40% | ▼ −2.27% | $0.0967 (+92.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers